The FDA’s final guidance on expanded access to investigational drugs does not add any new questions since the November 2022 draft guidance but does expand its discussion of the categories of access and adds a subcategories table that details key distinctions of the eight subcategories as well as the IRB requirements and waiting period before treatment may begin. The three maj... Read More